MedTrace Logo

Real-life First Dose Effect of Fasenra in Patients With Severe Uncontrolled Asthma

NCT04200326 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 5

Last updated 2021-04-08

No results posted yet for this study

Summary

This pilot study will use novel technologies to collect information about the patient experience before and early after starting Fasenra (benralizumab) as standard of care for severe uncontrolled asthma in a real-world setting, to determine how the experience changes over time. Any detection of an early, subjective first-dose effect in this pilot study will be further validated in a larger follow-up study.

Conditions

  • Severe Uncontrolled Asthma

Sponsors & Collaborators

Principal Investigators

  • Lynn Hagger · Astra Zeneca R&D

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-12-20
Primary Completion
2020-04-09
Completion
2020-04-09

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04200326 on ClinicalTrials.gov